Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized CSL787 for non-cystic fibrosis bronchiectasis
NL-OMON59017Phase 2Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of CSL787 in bronchiectasis, sponsored by CSL Behring. Primary endpoint: Time to first exacerbation. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
CSL787
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON59017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59017.